search results for

refine results

sort by


result type


Press Releases

EpiPen competitor Auvi-Q comes back Feb. 14 with a pricing scheme that will blow your mind

Have allergies? This EpiPen rival has a list price of $4,500, but most patients won't pay a cent.


Kaleo Auvi-Q list price 6x more than EpiPen

CNBC's Meg Tirrell reports Kaleo is bringing back EpiPen competitor Auvi-Q, but that it will be listed at $4,500.


Mallinckrodt to pay $100M to settle FTC charges

Mallinckrodt is to pay $100 million to settle FTC charges that it illegally maintained a monopoly of a special drug used on infants. CNBC's Meg Tirrell reports.


Mallinckrodt erases losses, says they settled with FTC

CNBC's Meg Tirrell reports that Mallinckrodt has settled with the FTC over a potential monopoly situation over one of its drugs.


Bayer, Monsanto tout jobs, investment pledge to Trump, but analysts question how much is new

After a meeting with President-elect Donald Trump, Bayer and Monsanto pledged jobs and investment, but is this spending new? Analysts have their doubts.


Bayer pledges billions in US investments

According to Trump's transition team, Bayer will commit to $8 billion in new research and development jobs in the U.S. CNBC's Meg Tirrell reports.


Collaboration in a world where everything is connected

Technology has the potential to answer our biggest questions, solve some of our toughest challenges and help us better understand the world around us.


Closing Bell Exchange: Whole new world in technology

Discussing the current state of the markets with with Meg Green, Meg Green & Associates; Keith Bliss, Cuttone & Co.; and Holly Liss, BTIG.


Gilead CEO: M&A is top of mind for us this year

John Milligan, Gilead president and CEO, speaks to CNBC's Meg Tirrell about potential M&A, drug-pricing pressure under President-elect Donald Trump and the company's hepatitis C drugs.


Mylan CEO: Trump a very business-minded, solution-oriented individual

Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing under President-elect Donald Trump as he pushes to bring drug prices down.